Biogen moves forward with Alzheimer’s drug trial

Biogen is moving its experimental Alzheimer’s drug, diranersen, to late-stage testing, despite disappointing results in mid-stage trials. The company said the drug, which targets tau, a protein associated with the disease, failed to show better responses at higher doses.

However, Biogen plans to advance the drug to Phase 3 testing due to signals suggesting it decreases tau levels and slows cognitive decline, particularly at the lowest dose.

Dr. Priya Singhal, Biogen’s head of development, said the results are compelling, noting the treatment’s ability to reduce tau and provide cognitive benefits.

“We’re really excited that we’ve been able to demonstrate an unprecedented combination of tau reduction in pathology and the cognitive benefit and have been really getting close to isolating a dose,” she said.

The decision marks the latest development in Biogen’s efforts to develop Alzheimer’s treatments, which have been marked by controversy and setbacks, including the withdrawal of its first drug, Aduhelm.

Biogen has brought two Alzheimer’s drugs to market, Aduhelm and Leqembi, both of which remove amyloid from the brain. Diranersen works differently, as an antisense oligonucleotide that limits tau production. They are now focusing on experimental drugs like diranersen.

Rival Eli Lilly is also studying tau-targeting drugs, highlighting the ongoing efforts to develop effective treatments for Alzheimer’s.

Alzheimer’s Treatment Development

Biogen’s journey to develop Alzheimer’s drugs has been uneven, with years of research and controversy surrounding its approvals. The company’s decision to move diranersen to late-stage testing is based on the drug’s potential to address the underlying causes of the disease, rather than just its symptoms.

Tau reduction and cognitive benefits are key factors in the development of effective Alzheimer’s treatments, and Biogen’s results suggest diranersen may offer a promising approach. It is essential for companies to make every call count in their research and development process.

As the search for effective Alzheimer’s treatments continues, companies like Biogen and Eli Lilly are pushing forward with innovative approaches, including antisense oligonucleotides and other tau-targeting therapies.

Current Research and Developments

According to the report, Alzheimer’s disease affects millions of people worldwide, and the development of effective treatments is a major public health priority. The disease is a significant concern, much like the summer box office is a significant event in the entertainment industry.

Researchers are exploring various approaches to address the disease, including tau-targeting therapies, amyloid-reducing treatments, and other innovative methods. They are playing a crucial role in advancing our understanding of Alzheimer’s and developing potential treatments.